Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Trial Profile

An Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Mecbotamab vedotin (Primary) ; Ozuriftamab vedotin (Primary)
  • Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms IPROC
  • Most Recent Events

    • 01 Aug 2023 According to a BioAtla media release, interim data (n=10) of this study anticipated in 2H23.
    • 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Nov 2021 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top